About
Founded in 1965, Adimmune is the first in Taiwan to comply with GMP standards of the FDA and the EU
History
The Cell Culture Production Plant received Taiwan Food and Drug Administration (FDA) PIC/S GMP certificate in 2022.
2023
- EnVAX-A71, developed by Enimmune, was granted Marketing Authorization in Taiwan
2022
- The Cell Culture Plant received Taiwan Food and Drug Administration (FDA) PIC/S GMP certificate
- AdimFlu-S (QIS), quadrivalent influenza vaccine, received marketing authorization in China
2021
- Adimmune signed a memorandum of understanding with Becton Dickinson
In January 2020, Adimmune extended the partnership with Sanofi Pasteur untill 2027
2020
- Extension of partnership with Sanofi Pasteur untill 2027
- Enimmune’s rapid test kits for COVID-19 received European CE Marking for In Vitro Diagnostic certificate
2019
- AdimFlu-S (QIS), quadrivalent influenza vaccine, received marketing authorization in Thailand
2017
- The Fill and Finish Plant received the Brazilian PIC/S GMP certificate
- AdimFlu-S (QIS), quadrivalent influenza vaccine, received marketing authorization in Taiwan
2016
- The Fill and Finish Plant received the U.S. FDA PIC/S GMP certificate
Adimmune signed a Cooperation Framework Agreement with Kitasato Daiichi Sankyo Co. in September 2015.
2015
- Adimmune signed a Cooperation Framework Agreement with Kitasato Daiichi Sankyo Co., Ltd.
- The Fill and Finish Plant received the EU GMP certificate
- AdimFlu-S (TIS), trivalent influenza vaccine, received marketing authorization in China
- Adimmune received Taiwan FDA validation for GDP standard of excellent pharmaceutical transportation
2014
- Enimmune Corporation was established as a subsidiary of Adimmune
- The Flu Antigen Production Plant and the Fill and Finish Plant received Taiwan FDA PIC/S GMP certificate
- Adimmune partnered with Sanofi Pasteur in providing aseptic fill and finish services
- Adimmune was awarded the Talent Quality-Management System Review Copper Award from the Taiwan Workforce Development Agency
2013
- Licensure of Phase I clinical trial of enterovirus 71 vaccines between the National Health Research Institute and Adimmune was launched
- Adimmune partnered with Techdow Pharm Co., Ltd. for a sterile filling service
- Adimmune cooperated with UMN, a global leader in recombinant protein vaccine manufacturing
2012
- The aseptic pre-filled syringe line received the Taiwan FDA PIC/S GMP certificate
2011
- Adimmune was awarded the National Biotech-Medical Quality Gold Award
- The Flu Antigen Production Plant received the EU GMP certificate
In June 2009, Adimmune inaugurated the Flu Antigen Production Plant.
2010
- Adimmune was awarded the Merit Medal Award from Executive Yuan for pandemic control of H1N1
- The Deloitte Asia-Pacific High-Tech High-Growth Evaluation ranked Adimmune as the 8th in Taiwan, 64th in the Asia-Pacific region
2009
- Under the New Biotechnology Ordinance, Adimmune was certificated as a biotechnology company by the Ministry of Economic Affairs
- Adimmune inaugurated the Flu Antigen Production Plant
2008
- The Japanese Encephalitis DNA vaccine received Taiwan patent
2007
- Crucell B.V. (The Netherlands) became a strategic stakeholder
The ground-breaking ceremony of the Flu Antigen Production Plant in 2002.
2005
- Adimmune signed a technology transfer agreement with Kitasato Institute
- Received the “Sullivan & Frost Award for Growth Strategy”
- Received the grant from Ministry of Economic Affairs for “Industrial Technology Development Plan for Cell Culture Process Platform of Japanese Encephalitis Vaccine”
2002
- Licensure of the human biological agent manufacturing technology between Taiwan Centers for Disease Control and Adimmune was launched
- Construction of the Flu Antigen Production Plant began
2001
- The name of the company was changed to “Adimmune Corporation”
In 1965, “Kuo Kwang Serum and Vaccine Manufacture Co., Ltd.” was founded in Shulin Township, Taipei County
1998
- Received the Ministry of Economic Affair’s “Industrial Technology Development Plan for Production of Japanese Encephalitis Vaccine by Cell Culture Process” grant (Early stage)
- Received “the 8th Annual Award for Biotechnology Industry Development” by Taiwan Bio Industry Organization
1967
- Kuo Kwang signed official technical support and import/export agreement with Kitasato Institute
1965
- “Kuo Kwang Serum and Vaccine Manufacture Co., Ltd.” was founded in Shulin Township, Taipei County